252 results about "Cellular infiltration" patented technology

The invention relates to the technical field of biological medicine, and discloses a pharmaceutical composition of paclitaxel dimer prodrug nanoparticles and a traditional Chinese medicine compound and application of the pharmaceutical composition, and the pharmaceutical composition is composed of Qiyuansanlong prescription freeze-dried powder and paclitaxel dimer prodrug nanoparticles; wherein the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) or GSH (glutathione) response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs), and the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) and GSH response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs). According to the pharmaceutical composition disclosed by the invention, a traditional Chinese and western medicine synergistic treatment system is innovatively constructed, and the advantage of multi-dimensional synergistic interaction is shown. Firstly, an NQO1 / GSH double-response type intelligent release system is adopted, and a biomarker highly expressed by tumor tissue can be specifically responded to realize precise drug release, so that the PTX concentration in tumors is improved compared with that of a traditional dosage form, and meanwhile, the drug circulation time is prolonged. Secondly, the active ingredients in the Qiyuansanlong prescription freeze-dried powder can significantly down-regulate the PD-L1 expression level, synergistically enhance CD4 + T and CD8 + T cell infiltration, and form chemical-immune dual killing effects.

The invention discloses bioactive macroporous hydrogel as well as a preparation method and application thereof. The bioactive macroporous hydrogel comprises hydrogel particles and a bioactive load loaded on the hydrogel particles, the hydrogel particles are obtained by mechanically extruding a hydrogel matrix, and the hydrogel matrix is formed by compounding sodium alginate, agarose and methacrylated hyaluronic acid through hydrogen bond crosslinking and photo-crosslinking; the bioactive load comprises: a) small extracellular vesicles of which the surfaces are modified with macrophage targeted CRV peptides; and b) a PLGA (poly (lactic-co-glycolic acid)) microsphere loaded with a cartilage inducer Kartogenin. The bioactive macroporous hydrogel disclosed by the invention has an internally communicated macroporous network, is beneficial to cell infiltration, blood vessel ingrowth and nutrient substance diffusion, and overcomes the defects that the traditional hydrogel is small in pore size and limits cell behaviors. According to the bioactive macroporous hydrogel disclosed by the invention, dual bioactive loads are adopted to synergistically promote tendon-bone healing, so that the treatment effect is better.

The invention belongs to the technical field of biological medicines, and particularly discloses a nano-engineering T cell membrane coated nano-particle as well as a preparation method and application of the nano-engineering T cell membrane coated nano-particle. Nanoparticles of a specific structure are constructed based on a phospholipid bilayer bionic nanometer platform through a membrane fusion technology, immune clearance caused by phagocytosis of the nanoparticles by macrophages can be avoided through disguise of a T cell membrane, and the blood circulation time is prolonged; the functions of T cells are recovered through specific blocking of immune checkpoint molecules loaded on the immune checkpoint molecules on corresponding immune checkpoint ligands on tumor cells; under ultrasonic radiation, the nano-particles are gradually decomposed and release the sound-sensitive agent to generate a large amount of active oxygen, so that immunogenic death of tumor cells is promoted, more cytotoxic T lymphocytes are recruited to infiltrate into tumor parts, and the recovery of T cell mediated immune response function is facilitated. The synergistic effect of the sound-sensitive agent and the immune checkpoint protein can effectively inhibit tumor growth, induce a long-term immune memory effect and prevent tumor metastasis and recurrence.

The invention discloses an engineered NK cell and a preparation method thereof. The antitumor activity of the NK cell is enhanced through synergistic modification of a fusion polypeptide and an anti-TIGIT monoclonal antibody. The amino acid sequence of the fusion polypeptide is shown as SEQ ID NO.1. The fusion polypeptide can specifically target tumor cells and activate the proliferation and killing functions of NK cells. And the anti-TIGIT monoclonal antibody further relieves the immunosuppression by blocking a TIGIT-CD155 signal channel. In-vitro experiments show that the killing rate of the combined modified NK cell on various solid tumors is obviously higher than that of the traditional CAR-NK cell. A PDX model shows that the engineered NK cells significantly inhibit tumor growth and enhance NK cell infiltration in a tumor microenvironment. The invention provides a new strategy with high efficiency and low toxicity for immunotherapy of solid tumors.

The invention belongs to the technical field of biological medicines, and discloses a traditional Chinese medicine composition for treating microsatellite stability (MSS) type tumors by a sensitization immune checkpoint inhibitor. The traditional Chinese medicine composition provided by the invention comprises radix scutellariae, rhizoma zingiberis, Chinese herbaceous peony, liquorice root and Chinese date, can increase CD8 + T cell infiltration, promote the CD8 + T cell to secrete cytokines and improve the immunosuppression of MSS type tumors, and further breaks through the conventional range of anti-tumor treatment of immune examination inhibitors; meanwhile, the traditional Chinese medicine composition can also improve adverse reaction of gastrointestinal tracts caused by tumor treatment by an immune examination inhibitor, and the life quality of patients is improved.

The invention discloses a dual-targeting macrophage membrane nano system and a preparation method and application thereof, and belongs to the field of biological medicine, MKA is wrapped in a macrophage membrane after AuNPs and mitochondrial targeting peptide KLA are connected. The preparation method comprises the following steps: firstly synthesizing AuNPs and modifying, and then wrapping with a macrophage membrane. In treatment, the compound can realize double targeting of tumor cells and mitochondria, enhance radiation-induced DNA damage, inhibit DDR, activate immune pathways and promote T cell infiltration, and can also consume glutathione and amplify oxidative stress to enhance immune effect, and the dose enhancement ratio of the compound in cooperation with 8GyX-rays reaches 3.1. In addition, the MKA is good in biocompatibility in vivo, long in blood circulation time, high in tumor targeting and capable of being quickly cleared through the kidney. The invention provides a new way for tumor radioimmunotherapy, and is helpful for promoting the progress of clinical tumor treatment.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can reduce the levels of MDA and NO in serum of mice and improve the activity of SOD and CAT and the content of GSH so as to relieve oxidative stress injury; inflammatory cell infiltration of nasal mucosa is reduced, and lung tissue inflammatory mediator level and inflammation-related gene expression are reduced to inhibit inflammation; th1 / Th2 immune balance is regulated, Th2 type cytokines are reduced, Th1 type cytokines are increased, and the high-dosage effect is close to that of loratadine. The strain has a treatment effect on allergic rhinitis through multiple mechanisms, and a new choice is provided for treatment of the strain.

The invention discloses a polyethylene glycol modified gold and manganese dioxide nano particle and a preparation method and application thereof, and belongs to the technical field of biological medicine, the polyethylene glycol modified gold and manganese dioxide nano particle (GMCN and PEG) has good biocompatibility under neutral physiological conditions, can relieve tumor hypoxia and increase generation of active oxygen in acidic TME, and has a good anti-tumor effect. The radiotherapy sensitivity is improved; and immune cell death is induced. Meanwhile, a cGAS-STING signal channel can be activated, dendritic cell maturation, macrophage M1 polarization and T cell infiltration are promoted, and the immunosuppression state in TME is counteracted. In addition, the GMCN-coated PEG also has an MR-CT bimodal imaging enhancement function, and integration of diagnosis and treatment is realized. The nano sensitizer disclosed by the invention has huge potential in the aspects of improving the radiotherapy curative effect, remodeling the tumor microenvironment, promoting the anti-tumor immunity, enhancing the biomedical imaging and the like.

The invention provides a preparation method of a composite artificial flap with a bionic structure and function induction activity. The preparation method comprises the following steps: S1, preparing an epidermis induction layer; s2, preparing a dermis functional remodeling layer; s3, preparation of a vascularization integration substrate layer; and S4, three-layer compounding and sterilization. Through an epidermis-basilar membrane-dermis three-layer integrated structure, a micron-nano multistage gradient pore and basilar membrane belt adhesion structure of natural skin is accurately simulated, and the problems of epidermis-dermis layering and non-uniform cell infiltration of an existing skin flap are solved.

The invention relates to a polypeptide derivative for pancreas islet surface modification and inhibition of pancreas islet transplantation IBMIR reaction, and belongs to the technical field of biological medicine. The peptide derivative disclosed by the invention is obtained by carrying out an amide reaction on KF7 peptide and levodopa, and the amino acid sequence of the KF7 peptide is shown as SEQ ID NO: 1. The polypeptide derivative has good biocompatibility, the surface modification method is simple, the modification process has no influence on cell life activity, activation, aggregation, expansion and adhesion of platelets can be inhibited, the bleeding risk is reduced, a blood coagulation system is not influenced, pancreas islet intrahepatic colonization and pancreas islet functions after portal transplantation are enhanced, and the application prospect is wide. The composition can protect pancreas islet, prevent infiltration of platelets and CD11b + cells, inhibit pancreas islet transplantation IBMIR reaction, control blood sugar level, and prevent and treat diabetes mellitus.

The invention belongs to the technical field of biological medicine, and particularly discloses nano composite particles based on a metal organic framework and a preparation method and application of the nano composite particles. The nano-composite particles are constructed through electron adsorption and coordination based on a nano-scale metal organic framework, and under the acidic microenvironment and ultrasonic irradiation of tumors, the nano-composite particles can be decomposed and released in a responsive manner, play a role of a sound-sensitive agent, generate a large amount of active oxygen and induce tumor cells to generate immunogenic death, so that the tumor cell immunogenicity is improved, and the tumor cell immunogenicity is improved. Further, more cytotoxic T lymphocytes are promoted to infiltrate a tumor microenvironment, T cell mediated anti-tumor immune response is recovered, and tumor metastasis is effectively prevented. The carrier metal organic framework ZIF8 of the nano-composite particles can serve as a sound-sensitive agent to generate active oxygen, the function of ultrasonic imaging of tumor tissue can be achieved, the effect of diagnosis is achieved while treatment is conducted, tumor diagnosis and treatment monitoring can be achieved at the same time through one-time drug administration, and a new strategy is provided for precise medical treatment.

The present disclosure describes membranes suitable for use in soft tissue repair applications that are composed of fibrous and highly porous biodegradable materials fabricated using electrospinning and that may be surface-modified with plasma treatment or other suitable methods of surface modification. The disclosed membranes have a high surface area to volume ratio. In some implementations, use of the disclosed membranes provides a barrier that prevents the migration of soft tissue cells but is permeable to small molecules such as nutritional substances and medications. In other implementations, use of the disclosed membranes provides a scaffold to facilitate soft tissue repair by providing a suitable environment for cellular infiltration and interaction to promote tissue regeneration. Methods of fabricating the disclosed resorbable membranes for soft tissue repair applications using electrospinning are also disclosed. The disclosed membranes may have precisely tuned physical, chemical, and mechanical properties optimized for various soft tissue repair applications.

The invention discloses an anti-tumor pharmaceutical composition based on NBDHEX and application of the anti-tumor pharmaceutical composition in treatment of immunosuppressive malignant tumors. The pharmaceutical composition comprises NBDHEX (6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio) hexanol) and a PD-1 (programmed death-1) inhibitor, and is characterized in that the NBDHEX (6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio) hexanol) and the PD-1 inhibitor are used as raw materials. The NBDHEX can induce tumor cells to generate immunogenic death and promote tumor antigen release, DAMPs signal activation and dendritic cell maturation, so that an immunosuppressive tumor microenvironment is remodeled, and CD8 + T cell infiltration and effector functions are enhanced. The pharmaceutical composition can significantly improve the anti-tumor immune response intensity and the treatment response rate. Animal experiments and cell experiments verify the synergistic anti-tumor effect of the composition in a lymphoma model. The immunosuppressive malignant tumors are suitable for treatment of various immunosuppressive malignant tumors including lymphoma, and are especially suitable for patients with poor single-drug reaction or drug resistance to immune checkpoint inhibitors, and a new way is provided for clinical treatment of tumors.

The invention relates to application of SMAD6 in auxiliary diagnosis and prognosis evaluation of TGCT (Transforming Growth Computed Tomography). According to the invention, a novel TGCT prognosis biomarker (SMAD6) is identified through difference analysis, Cox regression and survival analysis on the basis of a TGCT sample in multiple centers. Subsequently, the expression level of SMAD6 in normal testicular tissues and TGCT is evaluated through immunohistochemical staining. Finally, the relationship between the SMAD6 and biological characteristics, mutation landscape, immune cell infiltration and immunotherapy response is also studied. The invention defines that SMAD6 is a risk factor of poor TGCT prognosis. An immunohistochemical result shows that the SMAD6 is highly expressed in the TGCT tissue. GSEA shows that SMAD6 is related to activation of tumor-related pathways and inhibition of immune-related pathways. In addition, high SMAD6 expression is associated with lower CD8 + T cell infiltration, while patients with low SMAD6 expression gain more benefits in immunotherapy. The invention fully reveals the potential of SMAD6 as a TGCT prognosis and immunotherapy reaction biomarker, and provides a new scientific basis and theoretical basis for personalized treatment of TGCT.

The invention relates to the technical field of biological medicines, and discloses application of methionine adenosine transferase 2A and related substances thereof in preparation of wound repair products. According to the application disclosed by the invention, a metabolic regulation network in a diabetic wound surface is researched, so that MAT2A expression down-regulated in pericytes is found to be remarkably and negatively correlated with M1 type macrophage infiltration, and the situation that the wound healing is delayed, the wound surface blood perfusion is reduced and the inflammation macrophage infiltration is increased due to MAT2A specific deletion of the pericytes in the wound is observed; and after saMAT2A-loaded pericellular membrane coated lipid nanoparticles (PMCNPs) are further adopted for treatment, the regeneration process of the wound surface can be remarkably enhanced, continuous inflammatory macrophage infiltration in the diabetic wound surface is relieved, microcirculation recovery is promoted, the safety is high, and good application prospects are achieved in the aspect of promoting wound surface repair.

A use of liquiritin in the preparation of a drug for treating atopic dermatitis. Animal experiments show that liquiritin can remarkably lessen the skin lesion severity of an atopic dermatitis mouse model, reduce the ear thickness and the epidermal thickness, and reduce the infiltration degree of dermal lymphocytes, thereby demonstrating that liquiritin has a significant therapeutic effect on atopic dermatitis, has no toxic and side effects on the liver, the spleen and the kidney, and has good clinical application prospects and enormous social benefits, and expanding a new application field for a conventional leguminous plant liquorice extract, i.e., liquiritin.

The invention provides a novel medicine for treating psoriasis by recovering keratinocyte Pp6 and application of the novel medicine. The novel medicine has the structural formula shown in the formula (I), has the remarkable effects of inhibiting epidermal hyperplasia, reducing the infiltration number of dermal inflammatory cells and the like on a psoriasis focus area, and has the very excellent relieving or treating effect on psoriasis.

The invention discloses an engineered exosome for breaking through a pyroptosis immune starting and maintaining barrier as well as a preparation method and application of the engineered exosome. The exosome is constructed by loading an immune checkpoint inhibitor into a pre-stimulated exosome, and the exosome is derived from immune cells, high-expression interferon gamma and granzyme A. The expression of the tumor cell GSDMB is up-regulated by delivering the interferon gamma through the exosome, and the exogenous granzyme A cuts the GSDMB to trigger pyroptosis; meanwhile, an immune checkpoint inhibitor blocks a PD-1 / PD-L1 pathway in situ, T cell depletion is reversed, and release of endogenous granzyme A is promoted; the pyroptosis cells release antigens to activate the T cells, the activated T cells continuously secrete granzyme A / interferon gamma to form a cascade amplification effect, and the problem of double barriers existing in the pyroptosis immune cycle of granzyme A-GSDMB is solved. The engineered exosome can improve the infiltration degree of CD8 + T cells, and is suitable for treating tumors such as liver cancer and non-small cell lung cancer.

The application discloses application of DUSP4 in preparation of a marker for predicting the curative effect of immunotherapy of hepatocellular carcinoma and a sensitizing drug, and belongs to the technical field of biological medicine.The application finds that high expression of dual specificity phosphatase 4 (DUSP4) is significantly related to high response rate and long survival period of an immunological checkpoint blocking therapy for a hepatocellular carcinoma patient.DUSP4 promotes CD8+ T cell and NK cell infiltration and remodels an immune microenvironment by inhibiting a TGF-beta signal path, down-regulating an immunosuppressive factor and up-regulating an antigen presenting molecule and a chemotactic factor.The application provides a kit and a method for detecting the expression level of DUSP4 to predict an immunotherapy response, and a combined drug composition comprising a DUSP4 activator or a TGF-beta inhibitor and an immunological checkpoint inhibitor.Experiments prove that up-regulation of the expression of DUSP4 can significantly enhance T cell killing function, and produces a synergistic anti-tumor effect with an anti-PD-1 antibody.The application provides a new strategy for precise stratified treatment and overcoming immunological drug resistance of hepatocellular carcinoma.

The application relates to a cell infiltration inference method and system fusing GO function annotation and PPI network information, and the method comprises the following steps: collecting gene expression data, GO function annotation data and PPI network data; constructing a cell-cell function correlation network and a cell-cell physical interaction network respectively; performing weighted fusion processing on the two networks to obtain a comprehensive cell relationship network; calculating a final cell infiltration score through a restart walk algorithm, and inferring the infiltration degree in a tumor microenvironment according to the final cell infiltration score. The application innovatively fuses GO function annotation information and PPI network data, comprehensively considers the functional similarity and physical or signal interaction between cells, enables the model to understand cell synergy from the biological pathway level and analyze cell direct interaction from the protein interaction level, avoids one-sidedness of a single perspective, and provides a more stereoscopic cognitive framework for tumor microenvironment analysis.

The invention relates to the technical field of tumor molecular biology. The invention provides application of CTLA-4, TIM-3 and LAG-3 as immune checkpoints in screening of drugs for treating oral squamous cell carcinoma. According to the invention, expression differences of CTLA-4, TIM-3 and LAG-3 in oral squamous cell carcinoma tissues and normal tissues and correlation between expression of CTLA-4, TIM-3 and LAG-3 and CD8 + T cell infiltration are compared and analyzed, CTLA-4, TIM-3 and LAG-3 are screened as suitable immune checkpoints, and by inhibiting expression levels of CTLA-4, TIM-3 and LAG-3, activation and proliferation of T cells can be improved, positive regulation immune response can be increased, and the immunologic function of the oral squamous cell carcinoma is enhanced. Therefore, the oral squamous cell carcinoma treatment effect is improved.

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The invention discloses application of NCCRP1 as a lung adenocarcinoma immunotherapy biomarker, and belongs to the field of biological medicine. Bioinformatics analysis finds that the NCCRP1 is remarkably and highly expressed in lung adenocarcinoma tissues, and the expression level of the NCCRP1 is in negative correlation with prognosis of a patient. Secondly, the expression level of lung adenocarcinoma cells NCCRP1 is in negative correlation with infiltration of anti-tumor immune cells such as CD8 + T cells. Experiments show that the knockout of the NCCRP1 can significantly inhibit the growth of mouse lung tumors by increasing the infiltration quantity of CD8 + T cells and NK cells in a lung adenocarcinoma microenvironment. The invention provides a new target spot for immunotherapy of lung adenocarcinoma, including NCCRP1 gene editing (knockout / knockdown) and application of an inhibitor in preparation of antitumor drugs.

The invention relates to a cell infiltration inference method and system fusing GO function annotation and PPI network information. The method comprises the following steps: collecting gene expression data, GO function annotation data and PPI network data; respectively constructing a cell * cell function association network and a cell * cell physical interaction network; carrying out weighted fusion processing on the two to obtain a comprehensive cell relation network; and calculating a final cell infiltration fraction through a restart migration algorithm, and deducing the infiltration degree in the tumor microenvironment according to the final cell infiltration fraction. According to the method, GO function annotation information and PPI network data are creatively fused, functional similarity and physical or signal interaction between cells are comprehensively considered, the model can understand cell synergy from the biological pathway level and can analyze cell direct interaction from the protein interaction level, one-sidedness of a single view angle is avoided, and the method has the advantages of being simple in structure and convenient to operate. And a more three-dimensional cognitive framework is provided for tumor microenvironment analysis.

The invention provides a pharmaceutical composition for treating gastric cancer. The pharmaceutical composition comprises an NAT10 inhibitor and a PD-1 inhibitor. The gastric cancer is treated by combining the NAT10 inhibitor Remodelin with the PD-1 inhibitor, so that the problems of tumor angiogenesis and immunosuppression in existing treatment are solved, and the clinical curative effect of immunotherapy is improved. Research finds that when the Remodelin or the PD-1 inhibitor is independently used, a certain tumor inhibition effect is achieved, but the tumor volume of a combined treatment group is remarkably reduced, and immune cell infiltration is remarkably increased.

Provided relates to the field of cytometry, specifically to flow cytometric methods and kits for improved diagnosis, prognosis and monitoring of tumors and other lesions involving immune cell infiltration. Further provided are embodiments of the subject matter which relate to compositions and methods providing high resolution quantitative means for immunophenotyping and immune modeling, and for identification of disease prognostic and therapy predictive biomarkers.

The present invention provides a medicinally active extract obtained from the plant Polyspora axillaris ( Polygala japonica Houtt. ), which contains flavonol compounds of the following formula (I) as the first active ingredient, and optionally contains xanthone compounds of the following formula (II) as the second active ingredient and glycolipid compounds of the following formula (III-1) or (III-2) as the third active ingredient. Animal experiments have confirmed that the drug of the present invention is significantly superior to potassium sodium hydrogen citrate in typical test indexes such as calcium oxalate crystal aggregation, renal interstitial inflammatory cell infiltration and renal tubular dilation lesions, indicating that it has extremely good potential and market prospects in the treatment of urinary system lithiasis and urinary tract infections or kidney injuries caused by urinary system lithiasis, and as an adjuvant drug after surgical treatment of urinary system lithiasis. (I) (II) (III).

This invention relates to the field of traditional Chinese medicine and natural medicines, and discloses a traditional Chinese medicine composition for treating thyroiditis, nodular goiter, and thyroid nodules, as well as its preparation method and application. The traditional Chinese medicine composition is made from raw materials in parts by weight of 1-30 parts of Prunella vulgaris, 1-30 parts of Taraxacum mongolicum, 1-30 parts of Hordeum vulgare malt, 1-20 parts of Citrus reticulata peel, 1-24 parts of Crataegus pinnatifida, and 1-24 parts of Raphanus sativus seed. It can not only significantly reduce serum TgAb and TPOAb antibody levels, inhibiting the attack of autoimmune response on the thyroid gland from the source, but also effectively reduce lymphocyte infiltration, repair damaged thyroid follicular structure and restore colloid content, thereby reversing immune damage and tissue destruction of the thyroid gland, reducing thyroid nodules, and solving the problems of existing treatments for thyroiditis, nodular goiter, and thyroid nodules that cannot reverse immune damage to the thyroid gland, destruction of follicular structure, and tissue fibrosis.

The invention discloses application of a nerve injury induction protein 1 in preparation of a gastric cancer diagnosis and treatment product. The invention finds that the overexpression of NINJ1 not only can enhance the sensitivity of gastric cancer cells to ferroptosis by down-regulating the expression of aldehyde ketoreductase AKR1C1 / 2 / 3, but also can up-regulate the expression of MHC-I molecules on the surfaces of tumor cells, promote the presentation of tumor antigens and increase the infiltration of CD8 + T cells, so that the dual anti-tumor function is exerted; therefore, NINJ1 overexpression and an immune checkpoint inhibitor (such as a PD-L1 antibody) or a ferroptosis inducer are combined for use, so that the immunotherapy effect can be synergistically improved. The invention provides a brand new targeting strategy for overcoming the immune drug resistance of gastric cancer and improving the treatment effect, and has important clinical transformation value.

The application belongs to the technical field of biological medicine, and relates to application of a CXCL14 inhibitor in preparation of a drug for preventing or treating abdominal aortic aneurysm of a patient. The inhibitor effectively eliminates the gender difference of abdominal aortic aneurysm by specifically blocking the combination of CXCL14 and its receptor CXCR4, significantly reduces aortic macrophage infiltration and PDGFRA + macrophage accumulation in the progress of abdominal aortic aneurysm, reduces the degree of collagen degradation and elastic fiber damage, and thus inhibits the pathological progress of abdominal aortic aneurysm. The application provides a new target and drug combination for precise treatment of male abdominal aortic aneurysm, and has clear clinical application value.